A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies
Thursday, February 29, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Nurix is initiating a first-in-human Phase 1 trial for NX-2127, a novel Bruton’s Tyrosine Kinase dual-targeted protein degrader. This trial aims to evaluate its efficacy in patients with relapsed or refractory B-cell malignancies. The approach represents a significant advancement in the treatment landscape for these challenging cancers.
Price reaction · baseline $11.91 (2024-02-28 close) · hit pre-market · 1 other NRIX headline(s) in the window, move may be shared
day 0 close
+3.7%
Market Sentiment Analysis
POSITIVE FACTORS
First-in-human trial indicates innovative approach to treatment.
Focus on dual-targeted protein degradation shows potential.
Addresses unmet needs in relapsed/refractory B-cell malignancies.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-2127?
NX-2127 is a first-in-class Bruton’s Tyrosine Kinase dual-targeted protein degrader.
What type of trial is being conducted for NX-2127?
A first-in-human Phase 1 trial is being conducted to evaluate NX-2127.
Who are the patients targeted in this trial?
The trial targets patients with relapsed or refractory B-cell malignancies.
What is the goal of the NX-2127 trial?
The goal is to assess the efficacy of NX-2127 in treating specific B-cell malignancies.